MedPath

FDA Fast-Tracks Novel Drug PP-01 for Cannabis Withdrawal Syndrome Treatment

• PleoPharma's investigational drug PP-01 receives FDA Fast Track designation for treating cannabis withdrawal syndrome, addressing an unmet need with no current FDA-approved treatments.

• The once-daily oral medication targets CB1 receptors and mesolimbic reward pathway dysregulation, aiming to reduce withdrawal symptoms in cannabis use disorder patients.

• With approximately 19.2 million Americans affected by cannabis use disorder and only 1.64 million receiving treatment, PP-01's expedited development could significantly impact patient care.

PleoPharma Inc. has achieved a significant regulatory milestone as the US Food and Drug Administration (FDA) granted Fast Track designation to their lead investigational agent PP-01, developed to address cannabis withdrawal syndrome in patients with cannabis use disorder.
The designation marks a crucial advancement in addressing a condition that currently lacks FDA-approved treatment options. PP-01's development pathway will benefit from enhanced communication with regulatory authorities and potential rolling review of its new drug application, potentially accelerating its journey to market.

Innovative Mechanism of Action

PP-01 represents a novel therapeutic approach as a once-daily oral medication. The drug employs a dual mechanism of action, specifically targeting suppressed CB1 receptors while addressing neurotransmitter dysregulation within the mesolimbic reward pathway. This comprehensive approach aims to effectively manage withdrawal symptoms that often perpetuate cannabis dependence.

Addressing a Growing Public Health Challenge

Recent data from the Substance Abuse and Mental Health Services Administration (SAMHSA) highlights the urgent need for effective treatments. Approximately 19.2 million Americans currently meet the criteria for cannabis use disorder, with only 1.64 million receiving treatment. Among those seeking treatment, roughly one-third require intensive inpatient care, underscoring the severity of the condition.

Clinical Development and Company Perspective

As PleoPharma prepares to advance PP-01 into Phase 3 clinical trials, the company's leadership expressed optimism about the FDA's decision. "We are pleased that PP-01 has been granted Fast Track designation and are grateful to the FDA for recognizing the significance of cannabis withdrawal for the growing population with cannabis use disorder," stated Ginger Constantine, MD, CEO of PleoPharma.

Regulatory Implications and Future Outlook

The Fast Track designation provides PleoPharma with several key advantages in the drug development process. These include more frequent interactions with the FDA and the possibility of a rolling review for their new drug application. These regulatory benefits could significantly reduce the timeline for bringing PP-01 to patients who are actively seeking to discontinue cannabis use.
The development of PP-01 represents a potential breakthrough in addiction medicine, particularly as cannabis use disorder rates continue to rise in the United States. If successful in clinical trials, PP-01 would become the first FDA-approved treatment specifically designed to address cannabis withdrawal symptoms, filling a critical gap in current treatment options.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Denali Therapeutics' Tividenofusp Alfa Receives FDA Breakthrough Therapy Designation for Hunter Syndrome

Denali Therapeutics' tividenofusp alfa (DNL310) has received Breakthrough Therapy Designation from the FDA for Hunter syndrome (MPS II).
The designation aims to expedite the development and review of tividenofusp alfa, a potential improvement over existing therapies.

Replimune's RP1 Receives FDA Breakthrough Therapy Designation and BLA Submission for Advanced Melanoma

Replimune has submitted a Biologics License Application (BLA) to the FDA for RP1 in combination with nivolumab to treat advanced melanoma patients after anti-PD-1 therapy.
The FDA granted Breakthrough Therapy designation to RP1 plus nivolumab, expediting its development for patients with limited options after anti-PD-1 regimen failure.

FDA Approves Clinical Trial of Smoked Cannabis for PTSD Treatment in Veterans

The FDA has approved a Phase 2 clinical trial to study the safety and efficacy of smoked cannabis for treating PTSD symptoms in veterans.
The trial, funded by the Michigan Veteran Marijuana Research Grant Program, will involve 320 veterans with moderate to severe PTSD.

Replimune's RP1 Receives FDA Breakthrough Therapy Designation for Advanced Melanoma

Replimune's RP1, combined with nivolumab, has been granted Breakthrough Therapy designation by the FDA for advanced melanoma after anti-PD-1 treatment failure.
The BLA submission to the FDA for RP1 in combination with nivolumab was made under the Accelerated Approval pathway.

PP-007 Receives FDA Fast Track Designation for Acute Ischemic Stroke Treatment

The FDA granted Fast Track designation to PP-007, a novel therapy for acute ischemic stroke (AIS), based on promising safety and efficacy data from the HEMERA-1 trial.
PP-007 exhibits a unique combination of mechanisms, including opening collateral vessels, selectively delivering oxygen to hypoxic neurons, and reducing inflammation.

Prolong Pharmaceuticals' PP-007 Receives FDA Fast Track for Acute Ischemic Stroke

Prolong Pharmaceuticals' PP-007, a PEGylated carboxyhemoglobin, has been granted FDA Fast Track designation for acute ischemic stroke treatment.
The HEMERA-1 clinical trial is currently evaluating PP-007's safety and efficacy, showing promising results in combination with existing therapies.

FDA Grants Fast Track Designation to Prolong Pharmaceuticals' PP-007 for Acute Ischemic Stroke

The FDA has granted Fast Track designation to PP-007, Prolong Pharmaceuticals' investigational therapy, for acute ischemic stroke (AIS).
PP-007 is currently in the HEMERA-1 clinical trial, evaluating its safety and efficacy in U.S.-based patients with acute ischemic stroke.

FDA Grants Fast Track Designation to PP-007 for Acute Ischemic Stroke Treatment

Prolong Pharmaceuticals' PP-007 receives FDA Fast Track designation for acute ischemic stroke, potentially expediting its development.
PP-007 is under evaluation in the HEMERA-1 trial, showing promise in improving outcomes when combined with existing stroke treatments.

FDA Grants Fast Track Designation to VMT01 for MC1R-Positive Melanoma

The FDA has granted Fast Track designation to VMT01, a targeted alpha-particle therapy, for unresectable or metastatic melanoma expressing melanocortin 1 receptor (MC1R).
VMT01, developed by Perspective Therapeutics, delivers the alpha-emitting isotope 212Pb to tumor sites with MC1R overexpression, offering a novel approach to treatment.

NervGen Pharma Receives Fast Track Designation for NVG-291 in Spinal Cord Injury Treatment

NervGen Pharma Corp. has been granted Fast Track designation by the FDA for NVG-291, a novel treatment for spinal cord injury, aiming to expedite its development and review process. The Phase 1b/2a clinical trial is underway, with initial results anticipated by mid-2024.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy